Novartis India (NOVARTIND) Fundamentals 2026 — P/E 45.0x, Revenue Analysis | SniperIQ
Novartis India (NOVARTIND) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹4,195 Crore, trading at ₹1699.05 on the BSE. This SniperIQ fundamentals page covers Novartis India's valuation (P/E 45.0x, P/B 5.1x), profitability (net margin 26.3%), revenue (₹354 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Novartis India's market cap?
Novartis India (NOVARTIND) has a market capitalization of approximately ₹4,195 Crore, trading at ₹1699.05 on the BSE. Market cap moves with the live share price.
What is Novartis India's P/E ratio?
Novartis India's trailing twelve-month P/E ratio is 45.0x, with a price-to-book (P/B) of 5.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Novartis India?
Novartis India runs a net profit margin of 26.3%, a gross margin of 39.2%, and an operating margin of 26.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Novartis India generate?
Novartis India reported revenue of ₹354 Crore for fiscal year 2026, with net income of ₹93 Crore and earnings per share (EPS) of 37.74. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Novartis India pay a dividend?
Novartis India offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Novartis India financially healthy?
Novartis India carries a debt-to-equity ratio of 0.00x and a current ratio of 5.30x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Novartis India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Novartis India (NOVARTIND) the key facts are: market cap ₹4,195 Crore, P/E 45.0x, revenue ₹354 Crore, 52-week range 750-1722.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Novartis India's full fundamentals live
Get Novartis India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.